Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;59(12):4907-4914.
doi: 10.1007/s13197-022-05579-x. Epub 2022 Sep 1.

Human lactoferrin from breast milk: characterization by HPLC and its in vitro antibiofilm performance

Affiliations

Human lactoferrin from breast milk: characterization by HPLC and its in vitro antibiofilm performance

Karina Jeanette Parra-Saavedra et al. J Food Sci Technol. 2022 Dec.

Abstract

Preterm infants are at high risk of infection due to opportunistic bacteria as Pseudomonas aeruginosa, causing infections among infants in neonatal intensive care units. Human lactoferrin (hLf) is a multifunctional protein and one of the most abundant in breast milk, and plays an important role in prevention of different infections in neonates. This work offers a strategy to obtain a lyophilisate of purified lactoferrin from breast milk. In addition, a reliable HPLC method for quantification of lactoferrin with a linear quantification range of 0.040-0.140 mg/mL with selectivity, accuracy and repeatability, is described. Lyophilized hLf was obtained by purification through a heparin affinity column followed by ultrafiltration with a 30 kDa membrane. The final solution was lyophilized and the product was analyzed using HPLC method, recovering about 70% of initial lactoferrin in the sample. This molecule was elucidated through FTIR spectroscopy and SDS-PAGE electrophoresis. In addition, the capacity against biofilm formation of P. aeruginosa was demonstrated with 75% of inhibition at 6 mg/mL. These results suggest that lyophilized hLf can be obtained by purification of breast milk and that it can provide antibiofilm activity against P. aeruginosa.

Keywords: Antibiofilm activity; HPLC; Heparin column; Human lactoferrin; Lyophilized lactoferrin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe Author(s) declare(s) that they have no conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
Chromatograms of. A Ultrapasteurized milk used as sample blank, B hLf STD, and C Breast milk sample. There is no interference present at the same retention time as the hLf
Fig. 2
Fig. 2
FT-IR spectra of hLf STD and lyophilized lactoferrin. The spectrum of the sample has the same pattern of signals as for the standard, confirming the identity of the protein in the lyophilisate. The dotted lines show the most representative signals for the identification of lactoferrin
Fig. 3
Fig. 3
SDS-PAGE gel of hLf standard and lyophilized lactoferrin. The band of greatest intensity around 80 kDa corresponds to the molecular weight of lactoferrin. This band is present in the standard and the sample
Fig. 4
Fig. 4
Antibiofilm activity of lyophilized lactoferrin at various concentrations against Pseudomonas aeruginosa. Biofilm formation was measured after 24 h of incubation of bacteria with different concentrations of lyophilized lactoferrin. Bars represent the percentage of inhibition of biofilm, while the optical density of biofilm with the blue line is represented. The maximum antibiofilm activity was obtained at 6 mg/mL with 75% inhibition of biofilm formation. In addition, an inverse relationship between the percentage of inhibition and the optical density obtained for each concentration of the experiment is observed. Different letters show statistical significant differences (p < 0.05) by Tukey’s test

Similar articles

Cited by

References

    1. Bjarnsholt T, Buhlin K, Dufrêne YF, Gomelsky M, Moroni A, Ramstedt M, Römling U. Biofilm formation—what we can learn from recent developments. J Intern Med. 2018;284(4):332–345. doi: 10.1111/joim.12782. - DOI - PMC - PubMed
    1. Burrows LL. The therapeutic pipeline for Pseudomonas aeruginosa infections. ACS Infect Dis. 2018;4(7):1041–1047. doi: 10.1021/acsinfecdis.8b00112. - DOI - PubMed
    1. Chang R, Ng TB, Sun WZ. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents. 2020;56(3):106118. doi: 10.1016/j.ijantimicag.2020.106118. - DOI - PMC - PubMed
    1. Duca G, Anghel L, Erhan RV. Structural aspects of lactoferrin and serum transferrin observed by FTIR spectroscopy. Chem J Mold. 2018;13(1):111–116. doi: 10.19261/cjm.2018.482. - DOI
    1. Ellison RT, 3rd, Giehl TJ, LaForce FM. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun. 1988;56(11):2774–2781. doi: 10.1128/iai.56.11.2774-2781.1988. - DOI - PMC - PubMed

LinkOut - more resources